Latest Product Pipeline News

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Evolution Mining has taken a significant step toward its full acquisition of Carnaby Resources by acquiring a 13.7% stake from the QIC Queensland Critical Minerals Fund through a share issue, reinforcing its position as Carnaby’s largest shareholder.

Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.

XRF Scientific reported an 8% revenue increase to $64.4 million and a modest 1% rise in net profit after tax for FY26, underpinned by strong performances in Precious Metals and Capital Equipment divisions and the strategic acquisition of Bruker’s CGA business.

REA Group Ltd (ASX:REA) posted a robust FY26 with revenue up 7% to A$1.793 billion and core net profit rising 15% to A$682 million, supported by record audience engagement and strategic AI investments.

Pantoro Gold’s latest infill drilling at Racetrack within the Norseman Project reveals exceptional high-grade continuity, including a spectacular 1,737 g/t gold intercept, underpinning plans to ramp up underground production.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.